We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.

ReNeuron Receives UK Regulatory Approvals

ReNeuron Receives UK Regulatory Approvals

ReNeuron Receives UK Regulatory Approvals

ReNeuron Receives UK Regulatory Approvals

Read time:

Want a FREE PDF version of This News Story?

Complete the form below and we will email you a PDF version of "ReNeuron Receives UK Regulatory Approvals"

First Name*
Last Name*
Email Address*
Company Type*
Job Function*
Would you like to receive further email communication from Technology Networks?

Technology Networks Ltd. needs the contact information you provide to us to contact you about our products and services. You may unsubscribe from these communications at any time. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy

ReNeuron Group plc has announced that it has received final UK regulatory and ethical approvals to commence two new clinical trials, summarized below:

• Phase II clinical trial in stroke disability, recruiting up to 41 patients and treating 8-12 weeks post-stroke, regarded as the optimum treatment window for efficacy

• Second indication to enter the clinic - a Phase I clinical trial in critical limb ischaemia recruiting nine patients

• Both trials will use CTXcryo, the cryopreserved variant of ReNeuron’s CTX cell line which provides the drug product for both the stroke and critical limb ischaemia programmes

• CTXcryo formulation has significant cost of goods, shelf life and ease-of-use benefits

• Early adoption of CTXcryo avoids the likely need for subsequent, time-consuming bridging studies, thereby accelerating time to market.

A multi-centre Phase II clinical trial will be undertaken at NHS hospital trusts throughout the UK with the Company’s ReN001 investigational therapy for disabled stroke patients. The study will involve the treatment of up to 41 patients between 8 and 12 weeks after their stroke. Patients will be monitored on a number of validated stroke efficacy measures up to six months post-treatment.

The treatment window in the Phase II clinical trial is regarded as optimum in terms of the potential efficacy of the ReN001 therapy and differs from the treatment window in the Phase I clinical trial with ReN001 where patients were treated at least 6 months after their stroke.

The Phase II study has been adopted by the NHS National Institute for Health Research Stroke Research Network (SRN), enabling the Company to work closely with the SRN to optimize performance against defined targets regarding site set-up, patient recruitment and monitoring activities across the various sites participating in the study. The study is expected to read out by the end of 2015.

Alongside the Phase II stroke study with ReN001, the Company has already commenced a non-interventional, observational study in stroke patients, initially at a selection of the clinical sites that will participate in the Phase II study. The observational study will allow for the pre-screening of potentially eligible patients for the Phase II clinical trial at the sites concerned, enabling such patients to be identified in good time while still in acute stroke care at the hospital.

The observational study will also monitor eligible stroke patients who do not ultimately participate in the Phase II study with ReN001 on the same end-point measures, thus enabling a broad and valuable clinical data set to be built around the stroke patient sub-population targeted with the ReN001 therapy.

Separately, the Company has received final regulatory and ethical approvals to commence a Phase I clinical trial with its ReN009 investigational therapy for critical limb ischaemia (CLI). This major disease is common in patients with diabetes and can lead to amputation of the affected limb. The Company’s ReN009 therapy is a cell-based treatment for CLI patients which, in pre-clinical studies, has shown the potential to restore sufficient blood flow in the affected lower limb to avoid amputation, and therefore the severe health consequences that typically result from such a procedure.

The Phase I clinical trial with ReN009 will be undertaken through NHS Tayside at Ninewells Hospital and Medical School, Dundee, Scotland. In this dose escalation safety study, the ReN009 cells will be administered via straightforward intramuscular injection into the affected lower limb of nine patients with peripheral arterial disease (CLI is the end-stage of this disease). Patients will be monitored for up to 12 months to assess the safety and tolerability of the treatment. Assuming Phase I patient recruitment runs to plan, and assuming a good short term safety profile for the ReN009 investigational therapy in the study at the highest dose, the Company expects to be able to file for approval to commence a Phase II efficacy study with ReN009, as planned, during the first half of 2015.

Importantly, both the Phase II clinical trial with ReN001 and the Phase I study with ReN009 will utilize a reformulated, cryopreserved variant of the Company’s lead CTX stem cell line, designated CTXcryo. As previously announced, the Company has generated data demonstrating the equivalence of CTXcryo drug product to the original non-cryopreserved variant. These comparability data were recently submitted to the regulatory authorities as part of amended submissions for the above-mentioned Phase I and Phase II clinical trial applications.

The final regulatory approvals given for the studies will allow a significantly earlier than planned deployment of CTXcryo cells in clinical development, avoiding the need for bridging studies in the future and enabling ongoing clinical trial needs to be served much more efficiently and cost-effectively. The CTXcryo product variant will provide the business with major commercial and competitive advantages in terms of the availability of a genuine off-the-shelf cell-based treatment with a competitive cost of goods and a shelf life enabling shipping to, and storage at, clinical sites on a global basis.

Michael Hunt, Chief Executive Officer of ReNeuron, said: “We are delighted to have received these concurrent clinical trial approvals for our stroke and critical limb ischaemia programmes. It is especially pleasing to have been given approval to use our second-generation CTXcryo cells in both of these new clinical trials. The fact that this new product variant is being deployed clinically much earlier than we had planned is illustrative of ReNeuron’s ability, in collaboration with its various partners, to successfully innovate and sustain its commercial and competitive edge.”